Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Moestue, Siver A ^a   Borgan, Eldrid ^a,b   Huuse, Else M ^a   Lindholm, Evita M ^b   Sitter, Beathe ^a   Børresen Dale, Anne Lise ^b,c   Engebraaten, Olav ^b,c   Mælandsmo, Gunhild M ^b   Gribbestad, Ingrid S ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CHOLINE KINASE; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLYCEROPHOSPHORYLCHOLINE; GLYCINE; LYSOPHOSPHOLIPASE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2 GROUP IV; PHOSPHORYLCHOLINE; PROGESTERONE RECEPTOR; PROTEIN P53; TAURINE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; ENERGY METABOLISM; FROZEN SECTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; LIPID METABOLISM; LIPOGENESIS; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; QUANTITATIVE ANALYSIS; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BASAL CELL CARCINOMA; BREAST TUMOR; DNA MICROARRAY; DRUG SCREENING; FEMALE; GENETICS; HUMAN; METABOLISM; METABOLOME; PATHOLOGY; PROGNOSIS;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; METABOLOME; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLCHOLINES; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955523425     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-433     Document Type: Article

References (46)

1. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
4. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006, 8:R34. 10.1186/bcr1517, 1779468, 16846532.
5. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 2007, 16(Suppl 2):S72-S77. 10.1016/j.breast.2007.07.017, 17714947.
6. Mullins M, Perreard L, Quackenbush JF, Gauthier N, Bayer S, Ellis M, et al. Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. Clin Chem 2007, 53:1273-1279. 10.1373/clinchem.2006.083725, 17525107.
7. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006, 7:127. 10.1186/1471-2164-7-127, 1489944, 16729877.
8. Stadler ZK, Come SE. Review of gene-expression profiling and its clinical use in breast cancer. Crit Rev Oncol Hematol 2009, 69:1-11. 10.1016/j.critrevonc.2008.05.004, 18614375.
9. Banez-Coronel M, de Molina AR, Rodriguez-Gonzalez A, Sarmentero J, Ramos MA, Garcia-Cabezas MA, et al. Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets 2008, 8:709-719. 10.2174/156800908786733432, 19075594.
10. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res 1999, 59:3112-3118.
11. Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs 2001, 4:419-426.
12. Rodriguez-Gonzalez A, Ramirez de MA, Fernandez F, Ramos MA, del Carmen NM, Campos J, et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003, 22:8803-8812. 10.1038/sj.onc.1207062, 14654777.
13. Rodriguez-Gonzalez A, Ramirez de MA, Banez-Coronel M, Megias D, Lacal JC. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int J Oncol 2005, 26:999-1008.
14. Tozaki M. Proton MR spectroscopy of the breast. Breast Cancer 2008, 15:218-223. 10.1007/s12282-008-0048-x, 18443899.
15. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999, 59:80-84.
16. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 2007, 120:1721-1730. 10.1002/ijc.22293, 17236204.
17. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004, 64:4270-4276. 10.1158/0008-5472.CAN-03-3829, 15205341.
18. Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 2005, 7:287-326. 10.1146/annurev.bioeng.7.060804.100411, 16004573.
19. Mackinnon WB, Barry PA, Malycha PL, Gillett DJ, Russell P, Lean CL, et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 1997, 204:661-666.
20. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992, 5:303-324.
21. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006, 19:30-40. 10.1002/nbm.992, 16229059.
22. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. Radiology 2004, 233:424-431. 10.1148/radiol.2332031285, 15516615.
23. Morse DL, Raghunand N, Sadarangani P, Murthi S, Job C, Day S, et al. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts. Magn Reson Med 2007, 58:270-280. 10.1002/mrm.21333, 17654590.
24. Neeman M, Eldar H, Rushkin E, Degani H. Chemotherapy-induced changes in the energetics of human breast cancer cells; 31P- and 13C-NMR studies. Biochim Biophys Acta 1990, 1052:255-263. 10.1016/0167-4889(90)90219-4, 2334736.
25. Glunde K, Jie C, Bhujwalla ZM. Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia 2006, 8:758-771. 10.1593/neo.06187, 1584299, 16984733.
26. Morse DL, Carroll D, Day S, Gray H, Sadarangani P, Murthi S, et al. Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. NMR Biomed 2009, 22:114-127. 10.1002/nbm.1318, 19016452.
27. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002, 62:1966-1970.
28. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007, 7:659-672. 10.1038/nrc2193, 17721431.
29. Bergamaschi A, Hjortland GO, Triulzi T, Sorlie T, Johnsen H, Ree AH, et al. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 2009, 3:469-482. 10.1016/j.molonc.2009.07.003, 19713161.
30. Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 2002, 15:327-337. 10.1002/nbm.775, 12203224.
31. Sitter B, Bathen TF, Singstad TE, Fjosne HE, Lundgren S, Halgunset J, et al. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed 2010, 23:424-431.
32. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. Article3.
33. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000, 28:27-30. 10.1093/nar/28.1.27, 102409, 10592173.
34. Katz-Brull R, Margalit R, Degani H. Differential routing of choline in implanted breast cancer and normal organs. Magn Reson Med 2001, 46:31-38. 10.1002/mrm.1157, 11443708.
35. Michel V, Yuan Z, Ramsubir S, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med (Maywood) 2006, 231:490-504.
36. Gallazzini M, Ferraris JD, Burg MB. GDPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC. Proc Natl Acad Sci USA 2008, 105:11026-11031. 10.1073/pnas.0805496105, 2504799, 18667693.
37. Kreike B, van KM, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9:R65. 10.1186/bcr1771, 2242660, 17910759.
38. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004, 40:2667-2675. 10.1016/j.ejca.2004.08.021, 15571950.
39. Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2009, 2:444-455. 2655155, 19294003.
40. Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 1996, 16:1375-1380.
41. Ramirez de MA, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004, 64:6732-6739. 10.1158/0008-5472.CAN-04-0489, 15374991.
42. Gribbestad IS, Petersen SB, Fjosne HE, Kvinnsland S, Krane J. 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR Biomed 1994, 7:181-194. 10.1002/nbm.1940070405, 7946996.
43. Kvistad KA, Bakken IJ, Gribbestad IS, Ehrnholm B, Lundgren S, Fjosne HE, et al. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 1999, 10:159-164. 10.1002/(SICI)1522-2586(199908)10:2<159::AID-JMRI8>3.0.CO;2-0, 10441019.
44. Eliyahu G, Maril N, Margalit R, Degani H. Choline Metabolism in Breast Cancer; The Influence of the Microenvironmental conditions [Abstract]. Proc Intl Soc Mag Reson Med 2007, 15.
45. Giskeodegard GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjosne HE, et al. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res 2010, 9:972-979. 10.1021/pr9008783, 19994911.
46. Mori N, Glunde K, Takagi T, Xiong L, Wides F, Bhujwalla Z. Tumor microenvironmental alterations of lipid metabolism detected by comparing cancer cells with tumors [Abstract]. Proc Intl Soc Mag Reson Med 2009, 17:2310.